Interlocking gene mutations, epigenetic alterations and microenvironmental features
perpetuate tumor development, growth, infiltration and spread. Consequently, intrinsic and …

Chemotherapeutic and cytotoxic drugs are widely used in the treatment of cancer. In spite of
the improvements in the life quality of patients, their effectiveness is compromised by several …

The epidermal growth factor receptor (EGFR) is one of most potent oncogenes that are
commonly altered in cancers. As a receptor tyrosine kinase, EGFR's kinase activity has been …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Head and Neck Cancers focuses on glottic laryngeal cancer, which is the most common …

The epidermal growth factor receptor (EGFR) family consists of four members that belong to
the ErbB lineage of proteins (ErbB1–4). These receptors consist of an extracellular domain …

Head and neck squamous cell carcinoma (HNSCC) is a disease with heterogeneous clinical
behavior and response to therapies. Despite the introduction of multimodality treatment, 40 …

Head and neck squamous cell carcinoma (HNSCC) is the sixth most incident cancer
worldwide. More than half of HNSCC patients experience locoregional or distant relapse to …

Since the histone modifying enzymes EZH2 and HDACs control a number of epigenetic-
dependent carcinogenic pathways, we designed the first-in-class dual EZH2/HDAC inhibitor …

The epidermal growth factor receptor (EGFR) contributes to the pathogenesis of head&neck
squamous cell carcinoma (HNSCC). However, only a subset of HNSCC patients benefit from …

Background Activation of the MET oncogene promotes tumor growth, invasion and
metastasis in several tumor types. Additionally, MET is activated as a compensatory pathway …